Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

Stopped early · Phase 2

Conditions studied: Gonadotroph Adenomas

In brief

The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.

Key facts

Study ID

NCT00929669

Run by

University of Pennsylvania

People needed

2

Starts

2009-06-01

Expected to finish

2011-11-01

Last updated by the study team

2017-11-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• gonadotroph adenoma

You may not qualify if…

• visual impairment attributable to the adenoma
• radiation therapy
• active gallbladder disease
• uncontrolled diabetes

Where it is running

• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.